
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Sibylla Biotech and MD Anderson Collaborate on Small-Molecule Protein Degraders
Details : The collaboration aims to discover and develop novel small-molecule cancer therapies, Folding Interfering Degraders, which disrupt the proper folding of target proteins and lead to degradation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Sibylla Biotech Enters Strategic Collaboration with Ono for CNS Disorders
Details : Ono Pharmaceutical collaborates with Sibylla to use PPI-FIT technology for developing candidates for CNS disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration

Details : The proceeds of the Series A will allow the company to build out its pipeline of therapeutics by exploiting the protein folding simulation platform, as well as to further expand the potentiality of its technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 04, 2022

 Reset All
Reset All